MacroGenics Stock Price, News & Analysis (NASDAQ:MGNX) $8.71 -0.22 (-2.46%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$8.66▼$9.1050-Day Range$4.48▼$8.9352-Week Range$4.29▼$9.10Volume379,432 shsAverage Volume564,302 shsMarket Capitalization$540.28 millionP/E Ratio10.89Dividend YieldN/APrice Target$11.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability MacroGenics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.9% Upside$11.83 Price TargetShort InterestBearish11.00% of Float Sold ShortDividend StrengthN/ASustainability-1.61Upright™ Environmental ScoreNews Sentiment0.15Based on 2 Articles This WeekInsider TradingAcquiring Shares$669,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.73) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector151st out of 932 stocksPharmaceutical Preparations Industry52nd out of 431 stocks 3.5 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.83, MacroGenics has a forecasted upside of 35.9% from its current price of $8.71.Amount of Analyst CoverageMacroGenics has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.00% of the float of MacroGenics has been sold short.Short Interest Ratio / Days to CoverMacroGenics has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in MacroGenics has recently decreased by 4.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for MacroGenics is -1.61. Previous Next 2.9 News and Social Media Coverage News SentimentMacroGenics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MacroGenics this week, compared to 1 article on an average week.Search Interest10 people have searched for MGNX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows13 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $669,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 10.00% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to decrease in the coming year, from ($1.73) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is 10.89, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.24.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is 10.89, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 107.63.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MacroGenics Stock (NASDAQ:MGNX)MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.Read More MGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGNX Stock News HeadlinesDecember 8, 2023 | seekingalpha.comMacroGenics: This Top-Rated Stock Soars Big, But I'm Not BuyingDecember 6, 2023 | americanbankingnews.comMacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Buy" by AnalystsDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 30, 2023 | americanbankingnews.comReviewing MacroGenics (NASDAQ:MGNX) & Pfizer (NYSE:PFE)November 26, 2023 | benzinga.comMacrogenics Stock (NASDAQ:MGNX) Dividends: History, Yield and DatesNovember 8, 2023 | msn.comGuggenheim Upgrades Macrogenics (MGNX)November 7, 2023 | finance.yahoo.comMacroGenics (MGNX) Q3 2023 Earnings Call TranscriptNovember 7, 2023 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q3 2023 Earnings Call TranscriptDecember 10, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 6, 2023 | msn.comMacroGenics files for $300M mixed shelfNovember 6, 2023 | sfgate.comMacroGenics: Q3 Earnings SnapshotNovember 6, 2023 | finance.yahoo.comMacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comMacrogenics Inc (MGNX) Reports Q3 2023 Earnings: Net Income of $17. ...November 5, 2023 | markets.businessinsider.comWhat Wall Street expects from Macrogenics's earningsNovember 3, 2023 | benzinga.comA Preview Of Macrogenics's EarningsOctober 31, 2023 | finance.yahoo.comMacroGenics Announces Date of Third Quarter 2023 Financial Results Conference CallOctober 20, 2023 | markets.businessinsider.comPromising Outlook for MacroGenics Based on Daiichi-Merck Partnership and Phase 2 Asset DevelopmentSeptember 5, 2023 | finance.yahoo.comMacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research ProgramAugust 11, 2023 | msn.comHC Wainwright & Co. Reiterates Macrogenics (MGNX) Buy RecommendationAugust 11, 2023 | finance.yahoo.comMacroGenics, Inc. (NASDAQ:MGNX) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | finanznachrichten.deMacroGenics, Inc.: MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial ResultsAugust 10, 2023 | markets.businessinsider.comBMO Capital Remains a Buy on MacroGenics (MGNX)August 10, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for MacroGenics (MGNX)August 9, 2023 | finance.yahoo.comMacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial ResultsJuly 31, 2023 | finance.yahoo.comMacroGenics Announces Date of Second Quarter 2023 Financial Results Conference CallJuly 27, 2023 | finance.yahoo.comMGNX - MacroGenics, Inc.July 5, 2023 | finance.yahoo.comMacroGenics (NASDAQ:MGNX) shareholders have endured a 83% loss from investing in the stock three years agoSee More Headlines Receive MGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today12/10/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone(301) 251-5172Fax301-251-5321Employees357Year Founded2000Price Target and Rating Average Stock Price Target$11.83 High Stock Price Target$17.00 Low Stock Price Target$8.00 Potential Upside/Downside+35.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.80 Trailing P/E Ratio10.89 Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,760,000.00 Net Margins41.13% Pretax Margin41.13% Return on Equity-51.83% Return on Assets-25.18% Debt Debt-to-Equity RatioN/A Current Ratio5.68 Quick Ratio5.66 Sales & Book Value Annual Sales$151.94 million Price / Sales3.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.31 per share Price / Book3.77Miscellaneous Outstanding Shares62,030,000Free Float55,826,000Market Cap$540.28 million OptionableOptionable Beta2.08 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Scott Koenig M.D. (Age 71)Ph.D., President, CEO & Director Comp: $1.06MMr. James Karrels (Age 56)Senior VP, CFO & Corporate Secretary Comp: $626.83kMr. Eric Blasius Risser (Age 50)Chief Operating Officer Comp: $651.36kDr. Thomas M. Spitznagel Ph.D. (Age 56)Senior Vice President of Technical Operations Comp: $550.97kDr. Ezio Bonvini (Age 69)Senior VP of Research & Chief Scientific Officer Comp: $612.21kMr. Jeffrey Stuart Peters (Age 52)Senior VP, General Counsel & Corporate Compliance Officer Dr. Stephen L. Eck M.D. (Age 68)Ph.D., Senior VP of Clinical Development & Chief Medical Officer Comp: $577.62kMs. Lynn Cilinski (Age 65)VP, Controller & Treasurer More ExecutivesKey CompetitorsSavaraNASDAQ:SVRACalliditas Therapeutics AB (publ)NASDAQ:CALTPureTech HealthNASDAQ:PRTCTheravance BiopharmaNASDAQ:TBPHPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 7,215 shares on 12/1/2023Ownership: 0.401%Deutsche Bank AGSold 157,079 shares on 11/24/2023Ownership: 0.041%Graham Capital Management L.P.Sold 3,095 shares on 11/22/2023Ownership: 0.030%Jacobs Levy Equity Management Inc.Sold 5,502 shares on 11/17/2023Ownership: 0.644%Sectoral Asset Management Inc.Bought 34,504 shares on 11/15/2023Ownership: 0.624%View All Insider TransactionsView All Institutional Transactions MGNX Stock Analysis - Frequently Asked Questions Should I buy or sell MacroGenics stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks. What is MacroGenics' stock price target for 2024? 5 Wall Street research analysts have issued 1-year price objectives for MacroGenics' stock. Their MGNX share price targets range from $8.00 to $17.00. On average, they predict the company's share price to reach $11.83 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts. How have MGNX shares performed in 2023? MacroGenics' stock was trading at $6.71 at the beginning of the year. Since then, MGNX shares have increased by 29.8% and is now trading at $8.71. View the best growth stocks for 2023 here. When is MacroGenics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our MGNX earnings forecast. How were MacroGenics' earnings last quarter? MacroGenics, Inc. (NASDAQ:MGNX) issued its earnings results on Monday, November, 6th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.49. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to analysts' expectations of $54.80 million. MacroGenics had a net margin of 41.13% and a negative trailing twelve-month return on equity of 51.83%. What ETF holds MacroGenics' stock ? iShares Genomics Immunology and Healthcare ETF holds 221,160 shares of MGNX stock, representing 1.03% of its portfolio. What is Scott Koenig's approval rating as MacroGenics' CEO? 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC). Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (7.60%), Acadian Asset Management LLC (2.21%), Silverarc Capital Management LLC (2.04%), Rock Springs Capital Management LP (1.90%), Federated Hermes Inc. (1.50%) and Charles Schwab Investment Management Inc. (1.33%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel. View institutional ownership trends. How do I buy shares of MacroGenics? Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:MGNX) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.